...Epirus Biopharmaceuticals partnered with Livzon Mabpharm Inc. to develop, manufacture and commercialize up to five biosimilar antibodies in...

...Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) partnered with Livzon Mabpharm Inc. (Zhuhai City, China) to develop, manufacture and commercialize up...

...cash. The merger is slated to close this summer. Epirus' B round was led by Livzon Mabpharm Inc....

...is advising Zalicus, which was up $0.32 (31%) to $1.35 on Wednesday. Chinese biologics company Livzon Mabpharm Inc....